Jump to content

ADBICA

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Aethyta (talk | contribs) at 02:31, 23 April 2015 (Category:Designer drugs). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

ADBICA
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide
CAS Number
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H29N3O2
Molar mass343.46 g/mol g·mol−1
3D model (JSmol)
  • CCCCCN1C=C(C2=CC=CC=C21)C(=O)NC(C(=O)N)C(C)(C)C
  • InChI=1S/C20H29N3O2/c1-5-6-9-12-23-13-15(14-10-7-8-11-16(14)23)19(25)22-17(18(21)24)20(2,3)4/h7-8,10-11,13,17H,5-6,9,12H2,1-4H3,(H2,21,24)(H,22,25)
  • Key:IXUYMXAKKYWKRG-UHFFFAOYSA-N

ADBICA is a designer drug identified in synthetic cannabis blends in Japan in 2013.[1] ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers.[2] Nothing is known of the pharmacological activity of ADBICA in humans or other animals.


See also

References